These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11700789)

  • 1. Using health outcomes data to inform decision-making: formulary committee perspective.
    Janknegt R
    Pharmacoeconomics; 2001; 19 Suppl 2():49-52. PubMed ID: 11700789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
    Janknegt R; Steenhoek A
    Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTEGRATING HEALTH TECHNOLOGY ASSESSMENT PRINCIPLES IN FORMULARY MANAGEMENT.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP
    Int J Technol Assess Health Care; 2016 Jan; 32(1-2):81-7. PubMed ID: 27001376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The formulary decision-making process in a health maintenance organisation setting.
    Shepherd MD; Salzman RD
    Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pharmacoeconomic data in making hospital formulary decisions.
    Odedina FT; Sullivan J; Nash R; Clemmons CD
    Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees.
    Schiff GD; Tripathi JB; Galanter W; Paek JL; Pontikes P; Fanikos J; Matta L; Lambert BL
    Am J Health Syst Pharm; 2019 Apr; 76(8):537-542. PubMed ID: 30915453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The formulary decision-making process in a US academic medical centre.
    Nash DB; Catalano ML; Wordell CJ
    Pharmacoeconomics; 1993 Jan; 3(1):22-35. PubMed ID: 10146985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.
    Alabbadi I; Crealey G; Scott M; Baird S; Trouton T; Mairs J; McElnay J
    Clin Drug Investig; 2006; 26(9):485-94. PubMed ID: 17163281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Literature review on the structure and operation of Pharmacy and Therapeutics Committees.
    Durán-García E; Santos-Ramos B; Puigventos-Latorre F; Ortega A
    Int J Clin Pharm; 2011 Jun; 33(3):475-83. PubMed ID: 21416393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving rational therapeutics through consensus-based protocols and follow-up.
    Quintiliani R; Gousse GC; Chow MS
    Hosp Formul; 1990 Mar; 25(3):283-4, 289-94. PubMed ID: 10103836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of selective administration procedures in formulary maintenance.
    Quigley MA; Brown WM
    Hosp Pharm; 1981 Jul; 15(7):371-4, 378-80. PubMed ID: 10252001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision making.
    Janknegt R; Scott M; Mairs J; Timoney M; McElnay J; Brenninkmeijer R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S5-14. PubMed ID: 17931079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective decision-making in a changing healthcare environment: a P & T Committee interview.
    Zoloth A; Yon JL; Woolf R
    Hosp Formul; 1989 Feb; 24(2):85-7, 90, 93 passim. PubMed ID: 10291815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees.
    Hoffmann M
    Eur J Clin Pharmacol; 2013 May; 69 Suppl 1(Suppl 1):79-87. PubMed ID: 23640192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
    Shalansky SJ; Virk R; Ackman M; Jackevicius C; Kertland H; Tsuyuki R; Humphries K;
    Can J Cardiol; 2003 Feb; 19(2):173-9. PubMed ID: 12601443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.